VivoSeq
Dermatology

Generalized Pustular Psoriasis

12

Pipeline Programs↗

9

Active Trials↗

10

Companies Involved↗

Generalized Pustular Psoriasis is an emerging landscape with 12 programs across 10 companies. The most active players are Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd., Shanghai Huaota Biopharmaceutical Co., Ltd., Vanda Pharmaceuticals. 2 therapies are approved with 5 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

43/100

Pipeline Velocity

11/100

Mech. Concentration

29/100

Completion Rate

93/100

Attrition Rate

4/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

C

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

1 program

Phase 1S

Shanghai Huaota Biopharmaceutical Co., Ltd.

1 program

Phase 2V

Vanda Pharmaceuticals

1 program

Phase 2Chia Tai Tianqing Pharmaceutical Group Co., Ltd. logo

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

1 program

Phase 2AbbVie logo

AbbVie

1 program

Phase 3Takeda logo

Takeda

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

14programs
Monoclonal antibody857%
Small molecule643%

Modality classified for 100% of 14 pipeline programs.

Analysis

Trial Status

23

clinical trials

Completed13 · 57%
Active, not recruiting5 · 22%
Recruiting3 · 13%
Not yet recruiting1 · 4%
Terminated1 · 4%

Clinical Trials

Trial Activity

23 trials

Long-Term Safety and Efficacy of HB0034 in Subjects With Generalized Pustular Psoriasis
Recruiting·SShanghai Huaota Biopharmaceutical Co., Ltd.·Phase 2/3·NCT06477536·33 enrolled
A Clinical Trial of TQH2929 Injection in Patients With Acute Flare-up of Generalized Pustular Psoriasis
Recruiting·Chia Tai Tianqing Pharmaceutical Group Co., Ltd. logoChia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 2·NCT07314060·36 enrolled
Efficacy and Safety of HB0034 in Patients with Generalized Pustular Psoriasis (GPP)
Recruiting·SShanghai Huaota Biopharmaceutical Co., Ltd.·Phase 2·NCT06231381·33 enrolled
A Study of JNJ-77242113 for the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis
Active, not recruiting·Johnson & Johnson logoJohnson & Johnson·Phase 3·NCT06295692·19 enrolled
A Study of TAK-279 in Adult Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis
Active, not recruiting·Takeda logoTakeda·Phase 3·NCT06323356·18 enrolled
Effisayil™ ON: A Study to Test Long-term Treatment With Spesolimab in People With Generalized Pustular Psoriasis Who Took Part in a Previous Study
Active, not recruiting·Boehringer Ingelheim logoBoehringer Ingelheim·Phase 2·NCT03886246·131 enrolled
A Clinical Study of TQH2929 Injection in Treatment With Generalized Pustular Psoriasis (GPP)
Active, not recruiting·CChia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.·Phase 1·NCT06433531·9 enrolled
Effisayil® REP:An Open-label, Multicenter, Single-arm, Post-marketing Trial (in Select Countries) to Evaluate Efficacy and Safety and the Impact of Immunogenicity on Efficacy, Safety, and Pharmacokinetics of Spesolimab i.v. in Treatment of Patients With Generalized Pustular Psoriasis (GPP) Presenting With a Recurrent Flare Following Their Initial GPP Flare Treatment With Spesolimab i.v.
Active, not recruiting·Boehringer Ingelheim logoBoehringer Ingelheim·Approved·NCT06013969·42 enrolled
Spesolimab Post-marketing Surveillance in Korean Patients With Flares With Generalized Pustular Psoriasis
Not yet recruiting·Boehringer Ingelheim logoBoehringer Ingelheim·N/A·NCT06886009·21 enrolled
A Study to Assess Efficacy and Safety of Two Different Dose Regimens of Risankizumab Administered Subcutaneously in Japanese Subjects With Generalized Pustular Psoriasis or Erythrodermic Psoriasis
Completed·AbbVie logoAbbVie·Phase 3·NCT03022045·18 enrolled
A Study to Test Whether BI 655130 (Spesolimab) Prevents Flare-ups in Patients With Generalized Pustular Psoriasis
Completed·Boehringer Ingelheim logoBoehringer Ingelheim·Phase 2·NCT04399837·123 enrolled
Study to Assess the Efficacy, Safety and Tolerability of Secukinumab in Japanese Subjects With Generalized Pustular Psoriasis (GPP)
Completed·Novartis logoNovartis·Phase 3·NCT01952015·12 enrolled
A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in Adults With Generalized Pustular Psoriasis
Completed·VVanda Pharmaceuticals·Phase 2·NCT03619902·8 enrolled
Study to Investigate Efficacy and Safety of Adalimumab in Japanese Subjects With Generalized Pustular Psoriasis (GPP)
Completed·AbbVie logoAbbVie·Phase 3·NCT02533375·10 enrolled
A Study of Ixekizumab (LY2439821) in Participants in Japan With Generalized Pustular Psoriasis and Erythrodermic Psoriasis
Completed·Eli Lilly logoEli Lilly·Phase 4·NCT03942042·12 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)